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Abstract
The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd)
versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis
examined efficacy in patients with renal impairment (RI; estimated glomerular filtration rate <60 mL/min/1.73 m²). Isa
10 mg/kg was given intravenously once weekly in cycle 1, and every 2 weeks in subsequent 28-day cycles. Patients received
standard doses of Pd. Median progression-free survival (PFS) for patients with RI was 9.5 months with Isa-Pd (n= 55) and
3.7 months with Pd (n= 49; hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.30–0.85). Without RI, median PFS was
12.7 months with Isa-Pd (n= 87) and 7.9 months with Pd (n= 96; HR 0.58; 95% CI, 0.38–0.88). The overall response rate
(ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%). Complete renal response rates were
71.9% (23/32) with Isa-Pd and 38.1% (8/21) with Pd; these lasted ≥60 days in 31.3% (10/32) and 19.0% (4/21) of patients,
respectively. Isa pharmacokinetics were comparable between the subgroups, suggesting no need for dose adjustment in
patients with RI. In summary, the addition of Isa to Pd improved PFS, ORR and renal response rates.
Introduction
Renal impairment (RI) affects up to 50% of patients with
multiple myeloma (MM) [1]. In most patients, this is due to
the accumulation and precipitation of immunoglobulin free
light chains in the distal tubules, resulting in tubule
obstruction and cast nephropathy [1]. RI is an independent
predictor of adverse survival outcomes for myeloma
patients [2, 3] and the median survival of patients with RI is
approximately half that of patients without RI [2]. Anti-
myeloma treatments that can also improve renal function
are urgently required.
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Patients with RI are often excluded from or under-
represented in clinical trials [4, 5], and historically, the
criteria for renal improvement have been inconsistent
between studies. Recent International Myeloma Working
Group (IMWG) recommendations defined complete renal
response as an increase in estimated glomerular filtration
rate (eGFR) from <50 mL/min/1.73 m² at baseline to ≥60
mL/min/1.73 m² (eGFR ≥60; no RI) in at least one post-
baseline assessment [6]. Sustained complete renal responses
are complete responses lasting at least two months [7].
Based on its anti-myeloma capacity, and a route of
metabolism that is unaffected by renal function,
bortezomib-based regimens are currently recommended by
IMWG as the first choice of treatment for patients with
MM-related RI [6]. Bortezomib-based triplet therapy has
resulted in renal recovery in newly diagnosed patients with
RI [8], including when used in combination with melphalan
and prednisone, or doxorubicin and dexamethasone [9, 10].
The phase 3 MMY-3021 study demonstrated that similar
results for renal response are achieved with subcutaneous
administration of bortezomib [11].
Carfilzomib has also been shown to produce renal
responses. Subgroup analysis of the ENDEAVOR study
demonstrated complete renal response rates of 15.3%
among patients with relapsed/refractory MM (RRMM)
treated with carfilzomib and dexamethasone, with those
achieving complete renal responses demonstrating longer
median progression-free survival (PFS) and overall survival
(OS) than patients who did not achieve renal response [12].
However, carfilzomib has also been associated with renal
toxicity [13].
Ixazomib in combination with lenalidomide and
dexamethasone has shown good antitumor activity in
patients with RI [14], but no studies so far have reported
improvements in renal function.
One of the most widely used immunomodulatory
therapies, lenalidomide, is renally excreted, and so requires
dose adjustment in patients with RI, but is still considered
to be effective for the management of mild-to-moderate
RI [6].
Pomalidomide plus dexamethasone is well tolerated in
patients with MM refractory to lenalidomide and
bortezomib, including those with RI [15]. Unlike lenalido-
mide, pomalidomide does not require dose modification in
patients with RI [16]. In a phase 3 study, 32% of patients
treated with pomalidomide and low-dose dexamethasone
(Pd) achieved a complete renal response, defined in
accordance with the IMWG recommendations [17]. More-
over, Pd had comparable effects on OS, PFS and toxicity in
patients with and without moderate RI [17]. A further study
in patients with moderate RI (eGFR 30 to <45 mL/min/
1.73 m²) reported a sustained complete renal response in
18.2% of patients [18].
Few data exist exploring RI among patients receiving
monoclonal antibody therapy. Isatuximab (Isa) is an IgG1
monoclonal antibody that targets a specific epitope on
CD38, with several mechanisms of action against MM [19].
Administering Isa in combination with Pd in preclinical
studies was shown to increase its antitumor activity [19],
while a phase 1b study reported encouraging response rates
and PFS in patients with RRMM treated with the Isa-Pd
combination [20]. These benefits were confirmed in
ICARIA-MM, the first randomized, phase 3, active-
controlled trial to investigate the efficacy and safety of
Isa-Pd in patients with RRMM and ≥2 prior lines of therapy
[21, 22]. In the primary analysis, Isa-Pd showed a
statistically significant and clinically meaningful improve-
ment in PFS versus Pd (11.53 vs 6.47 months; hazard ratio
[HR] 0.596; 95% confidence interval [CI], 0.436–0.814;
P= 0.001) [22]. The patient population in ICARIA-MM
reflected the real-world setting, and included patients who
were heavily pretreated (median 3 [range, 2–11] prior lines
of therapy), with more than 70% of patients refractory to
both lenalidomide and a proteasome inhibitor (PI). In
addition, patients with eGFR ≥30 mL/min/1.73 m² were
eligible for inclusion and 36.2% of patients in ICARIA-MM
had RI (eGFR <60 mL/min/1.73 m²) [22]. Here, we report a
prespecified subgroup analysis of ICARIA-MM comparing
efficacy, renal response, and safety with Isa-Pd versus Pd,




ICARIA-MM (NCT02990338) was a prospective,
randomized, open-label, active-controlled, multicenter
phase 3 study [22]. Institutional review boards and inde-
pendent ethics committees of participating institutions
approved the protocol. The study was conducted according
to the principles of the Declaration of Helsinki and the
International Conference on Harmonisation Good Clinical
Practice Guidelines. All patients provided written informed
consent.
Patients
Details of the study methodology have been reported
previously [22]. Briefly, eligible patients with RRMM had
received ≥2 prior lines of therapy and had failed both
lenalidomide and a PI given alone or in combination.
Patients had progressed within 60 days of completing the
previous therapy. Patients with primary refractory disease
were excluded. Patients were included if they had a baseline
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eGFR of ≥30 mL/min/1.73 m² (moderate RI), determined
using the Modification of Diet in Renal Disease (MDRD)
equation [22].
Treatment
All patients received pomalidomide 4 mg orally on days
1–21 plus dexamethasone 40 mg (20 mg in patients ≥75
years old) orally or intravenously on days 1, 8, 15, and 22 of
each 28-day cycle. Patients randomized to the Isa-Pd
treatment arm also received Isa 10 mg/kg administered
intravenously on days 1, 8, 15, and 22 of cycle 1, then on
days 1 and 15 in each subsequent cycle.
Study endpoints and outcomes measured
PFS and OS
PFS was defined as the time from randomization to first
documentation of progressive disease, as determined by an
independent response committee, or death. Response was
assessed according to IMWG criteria using central lab data
for M-protein and central review of imaging [22]. OS was
defined as the time from randomization to death from
any cause.
Clinical response
Patients were assessed for clinical response at screening/
baseline, on day 1 of each treatment cycle, at the end of
treatment visit (30 days after the last dose of treatment), and
every 30 days until disease progression. Assessments inclu-
ded serum and 24-h urine M-protein quantification (by local
and central laboratory), quantitative immunoglobulins (local
and central laboratory), and imaging when appropriate.
Renal response
eGFR (calculated by MDRD) was assessed at screening,
within 24 h prior to study treatment administration on days
1, 8, 15, and 22 of cycle 1, and within 24 h prior to study
treatment administration on day 1 of every subsequent
cycle, at the end of treatment visit, and as clinically
indicated. eGFR results were classified as RI (<60 mL/min/
1.73 m²) or no RI (≥60 mL/min/1.73 m²); data were also
examined among patients with eGFR <45 mL/min/1.73 m².
Complete renal response was defined as an improvement in
eGFR from <50 mL/min/1.73 m² at baseline to ≥60 mL/min/
1.73 m² in at least one post-baseline assessment (IMWG
recommendations [6]). Responses were considered durable
(sustained) when lasting ≥60 days. A minor renal response
was defined as an improvement in eGFR from <15 mL/min/
1.73 m² at baseline to ≥15–<30 mL/min/1.73 m² or from
≥15–<30 mL/min/1.73 m² at baseline to ≥30 mL/min/1.73
min² in at least one assessment during treatment.
Safety
Safety assessments (including adverse events, serious
adverse events, laboratory parameters, vital signs, and
physical examination) were performed throughout the
study. All adverse events were graded according to National
Cancer Institute Common Terminology for Adverse Events
v4.03. Treatment-emergent adverse events (TEAEs) were
those that developed or worsened from the time of signed
informed consent to 30 days after last administration of
study treatment.
PK analyses
Isa concentration data were used for population PK analysis
after pooling data from the Isa-Pd arm (N= 148) with data
from single-agent studies (N= 284) and an Isa-Pd phase 1b
study (N= 44).
The PK analysis used Monolix 2018R1 software (Lixoft,
Antony, France) to characterize Isa nonlinear (target-
specific clearance) and linear (target-nonspecific clearance)
PK and its time-dependency, and identify the source of
intrinsic/extrinsic PK variability, including the effect of
renal function impairment.
Statistical analyses
Response rates were compared between treatment groups
using the stratified Cochran–Mantel–Haenszel test. PFS and
OS were analyzed between treatment groups using
Kaplan–Meier methodology and reported as median values
with 95% CIs. HRs were estimated using the stratified Cox
proportional hazards model and reported with 95% CIs.
Treatment arms were compared using a one-sided log-rank
test stratified by number of prior lines of therapy and age.
Comparisons between patients with and without RI were
observational only, with no formal statistical analysis per-
formed. SAS 9.4 (SAS, Cary, NC) was used for all analyses.
Results
Patients
Altogether, 307 patients were randomized to Isa-Pd
(n= 154) or Pd (n= 153). Of those, 142 and 145 patients
had evaluable eGFR, respectively; 12 and 8 patients were
not evaluable due to local legal restrictions on collecting
race information. Of patients evaluable for MDRD,
55 (38.7%) and 49 (33.8%) had RI at baseline, of whom
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with. . .
19 (13.4%) and 16 (11.0%) had eGFR ≥30–<45 mL/min/
1.73 m². Each arm had one patient with eGFR <30 mL/min/
1.73 m² who was included in the analysis. Baseline demo-
graphics and clinical characteristics were similar between
treatment arms, and between patients with and without RI at
baseline with the exception that patients with RI tended to
be older, have more International Staging System stage III
disease and more light chain disease than patients without
RI (Table 1). Patient flow has been described previously
[22].
Table 1 Baseline demographics and clinical characteristics.
eGFR <60 mL/min/1.73 m2 eGFR ≥60 mL/min/1.73 m2
Isa-Pd (n= 55) Pd (n= 49) Isa-Pd (n= 87) Pd (n= 96)
Median age, years (range) 71 (39–83) 67 (41–86) 66 (36–82) 64 (41–81)
Female, n (%) 22 (40.0) 26 (53.1) 38 (43.7) 54 (56.3)
Age categories, n (%)
<65 years 15 (27.3) 18 (36.7) 34 (39.1) 49 (51.0)
65–74 years 21 (38.2) 16 (32.7) 42 (48.3) 35 (36.5)
≥75 years 19 (34.5) 15 (30.6) 11 (12.6) 12 (12.5)
Median time since diagnosis, years (range) 4.4 (1.3–11.1) 4.5 (1.2–15.8) 4.9 (0.6–18.4) 4.0 (0.5–20.5)
Type of myeloma at diagnosis, n (%)
IgA 16 (29.1) 9 (18.4) 16 (18.4) 30 (31.3)
IgG 30 (54.5) 34 (69.4) 63 (72.4) 60 (62.5)
Light chain (κ+λ) 7 (12.7) 6 (12.2) 7 (8.0) 5 (5.2)
ISS stagea at diagnosis, n (%)
I 7 (12.7) 9 (18.4) 27 (31.0) 29 (30.2)
II 14 (25.5) 15 (30.6) 30 (34.5) 30 (31.3)
III 23 (41.8) 19 (38.8) 16 (18.4) 24 (25.0)
ISS stagea at study entry, n (%)
I 14 (25.5) 7 (14.3) 45 (51.7) 42 (43.8)
II 16 (29.1) 16 (32.7) 32 (36.8) 36 (37.5)
III 25 (45.5) 25 (51.0) 7 (8.0) 16 (16.7)
Median bone marrow plasma cells at study
entry, % (range)
32.0 (0–100) 30.0 (1.0–93.0) 23.6 (0–100) 30.0 (0–90.0)
Cytogenetic risk at study entryb, n (%)
High 9 (16.4) 11 (22.4) 11 (12.6) 22 (22.9)
Standard 36 (65.5) 29 (59.2) 63 (72.4) 47 (49.0)
Missing 10 (18.2) 9 (18.4) 13 (14.9) 27 (28.1)
Median prior lines of therapy (range) 3 (2–11) 3 (2–10) 3 (2–11) 3 (2–9)
Prior therapy, n (%)
Alkylating agent 49 (89.1) 47 (95.9) 80 (92.0) 93 (96.9)
Proteasome inhibitor 55 (100) 49 (100) 87 (100) 96 (100)
Lenalidomide 55 (100) 49 (100) 87 (100) 96 (100)
Refractory status, n (%)
IMiD refractory 52 (94.5) 44 (89.8) 83 (95.4) 92 (95.8)
Lenalidomide refractory 51 (92.7) 42 (85.7) 81 (93.1) 90 (93.8)
PI refractory 41 (74.5) 42 (85.7) 70 (80.5) 69 (71.9)
Lenalidomide and PI refractory 39 (70.9) 37 (75.5) 65 (74.7) 66 (68.8)
Lenalidomide last line 35 (63.6) 22 (44.9) 48 (55.2) 59 (61.5)
eGFR estimated glomerular filtration rate, Ig immunoglobulin, Isa isatuximab, ISS International Staging System, IMiD immunomodulatory drug,
Pd pomalidomide and dexamethasone, PI proteasome inhibitor.
aISS staging was derived based on the combination of serum β2-microglobulin and albumin.
bHigh risk was defined as del(17p), t(4;14), or t(14;16) by fluorescence in situ hybridization. Cytogenetics was performed by a central laboratory
with a cut-off of 50% for del(17p), and 30% for t(4;14) and t(14;16).
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Efficacy
PFS
The PFS benefit of Isa-Pd versus Pd in patients with and
without RI was consistent with that seen for the overall
study population. For patients with RI, median PFS was
9.5 months with Isa-Pd (n= 55) and 3.7 months with Pd
(n= 49; HR 0.50; 95% CI, 0.30–0.85) (Fig. 1a). For
patients with eGFR <45 mL/min/1.73 m², median PFS was
7.5 and 2.8 months (HR 0.50; 95% CI, 0.22–1.13) for
Isa-Pd (n= 20) and Pd (n= 17), respectively (Fig. 1b). In
patients without RI, median PFS was 12.7 months with
Isa-Pd (n= 87) and 7.9 months with Pd (n= 96; HR 0.58;
95% CI, 0.38–0.88) (Fig. 1c).
OS
OS data for the entire ICARIA-MM study are not yet
mature, but can be analyzed in the smaller RI subpopulation.
Median OS for patients with RI was not reached in the Isa-
Pd arm compared with 11.6 months in the Pd arm (HR 0.53;
95% CI, 0.30–0.96; Fig. 2a). For patients with eGFR
<45mL/min/1.73 m², median OS was 10.7 versus
6.6 months (HR 0.62; 95% CI, 0.26–1.45) for Isa-Pd versus
Pd (Fig. 2b). In patients without RI, median OS was not
reached in either arm (HR 0.62; 95% CI, 0.33–1.19; Fig. 2c).
ORR
The ORR was higher with Isa-Pd versus Pd, regardless of

























Median PFS: Isa-Pd 9.5 months, Pd 3.7 months 
HR 0.50 (95% CI 0.30–0.85)
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Fig. 1 Progression-free survival. Patients with eGFR <60 mL/min/
1.73 m² (a), <45 mL/min/1.73 m² (b), and ≥60 mL/min/1.73 m² (c) in
the Isa-Pd and Pd arms. CI confidence interval, eGFR estimated glo-
merular filtration rate, HR hazard ratio, Isa-Pd isatuximab, pomali-


























Median OS: Isa-Pd NR, Pd 11.6 months 
HR 0.53 (95% CI 0.30–0.96)
Isa-Pd <60 mL/min/1.73m² (n=55)
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Median OS: Isa-Pd 10.7 months, Pd 6.6 months 
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Fig. 2 Overall survival. Patients with eGFR <60 mL/min/1.73 m² (a),
<45 mL/min/1.73 m² (b) and ≥60 mL/min/1.73 m² (c) in the Isa-Pd and
Pd arms. CI confidence interval, eGFR estimated glomerular filtration
rate, HR hazard ratio, Isa-Pd isatuximab, pomalidomide, and
dexamethasone, OS overall survival, Pd pomalidomide and
dexamethasone, NR not reached.
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and Pd, respectively for patients with RI (odds ratio [OR]
3.98; 95% CI, 1.60–10.17). Among patients with RI, 32.7%
and 4.1% had a very good partial response or better with
Isa-Pd and Pd, respectively. Eight patients in the Isa-Pd arm
achieved minimal residual disease negativity (sensitivity
level 10−5), of whom three had an eGFR <60 mL/min/
1.73 m². No patients in the Pd arm achieved minimal resi-
dual disease negativity. The ORR for patients with eGFR
<45 mL/min/1.73 m² was 35.0% with Isa-Pd and 23.5%
with Pd (OR 1.75; 95% CI, 0.34–10.11). For patients
without RI, ORR was 67.8% and 42.7% with Isa-Pd and Pd,
respectively (OR 2.83; 95% CI, 1.48–5.42). ORR was
68.6% for patients with eGFR ≥45–<60 mL/min/1.73 m² in
the Isa-Pd arm (n= 35), which was noted to be similar to
that of patients without RI, whereas the ORR was 25.0% for
patients with mild RI in the Pd arm (n= 32).
Renal response
Complete renal response occurred in 71.9% (23/32) of
patients in the Isa-Pd arm and 38.1% (8/21) of those in the
Pd arm (OR 4.15; 95% CI, 1.12–15.78; Fig. 4). Durable
complete renal response was achieved more frequently with
Isa-Pd (31.3% [10/32]) than Pd (19.0% [4/21]) with OR
1.93; 95% CI, 0.45–9.82 (Fig. 4). In addition, one patient in
the Isa-Pd arm had a minor renal response. Median time to
renal response was 3.4 and 7.3 weeks for Isa-Pd and Pd,
respectively.
In patients evaluable for renal response (baseline eGFR
<50 mL/min/1.73 m²) in both the Isa-Pd and and Pd arms,
tumor response rates were higher in patients with renal
response than patients without renal response (Isa-Pd 52%
vs 44%; Pd 38% vs 23%).
Fewer patients in the Isa-Pd arm progressed to end-stage
renal disease (ESRD; eGFR <15 mL/min/1.73 m²) during
treatment with Isa-Pd versus Pd (2.9% vs 7.9%). Among
patients with moderate RI at baseline, renal function wor-
sened to severe RI or ESRD in 22.6% (12/53) of patients in
the Isa-Pd arm and 34.8% (16/46) of patients in the Pd arm
(OR 0.55; 95% CI, 0.20–1.45).
Safety
Treatment exposure
The median (range) number of cycles for patients with and
without RI was 10 (1–18) and 10 (1–19) cycles with Isa-Pd
(54 and 86 treated patients), and 5 (1–16) and 7 (1–18)
cycles with Pd (47 and 94 treated patients), respectively.
The median duration of exposure for patients with and
without RI was 41.6 (4.0–74.1) and 43.6 (3.1–76.7) weeks
with Isa-Pd, and 19.3 (1.0–65.0) and 28.6 (1.7–73.7) weeks
with Pd, respectively.
Adverse events
All patients with RI experienced TEAEs, while 85 (98.8%)
and 91 (96.8%) patients without RI experienced TEAEs in
the Isa-Pd and Pd arms, respectively (Table 2). The
incidence of grade 5 TEAEs, serious TEAEs, and TEAEs
leading to definitive treatment discontinuation was higher in
patients with versus without RI for both treatment arms
(Table 2). When all grade TEAEs were analyzed by type,
there was a ≥10% higher incidence of cardiac disorders and
infections in patients with RI versus without RI in the Isa-
Pd arm. The incidence of grade ≥3 TEAEs was similar for
patients with versus without RI (90.7% vs 86%) in the Isa-
Pd arm (Table 2). By type, in patients with RI, there was
a ≥10% higher incidence of grade ≥3 musculoskeletal dis-
orders and infections in the Isa-Pd arm. Among the grade ≥3
infections, there was a ≥10% higher incidence of pneumonia
that was also seen in the Pd arm (Table 2).
Table 3 shows the most common TEAEs according to
treatment arm and baseline renal function. The most
common TEAEs (≥15 % in all arms) were neutropenia,

































































Fig. 3 Response rates. Overall response rate and depth of response
according to renal function in patients treated with Isa-Pd and Pd. †One
patient in each arm had eGFR <30 mL/min/1.73 m²; the treatment
response was stable disease for the patient in the Isa-Pd arm and
progressive disease for the patient in the Pd arm. CR complete
response, eGFR estimated glomerular filtration rate, Isa-Pd
isatuximab, pomalidomide, and dexamethasone, ORR overall
response rate, Pd pomalidomide and dexamethasone, PR partial
response, sCR stringent complete response, VGPR very good partial
response.
Fig. 4 Renal response. Complete and durable (≥60 days) renal
responses in patients with eGFR <50 mL/min/1.73 m² at baseline in the
Isa-Pd and Pd arms. eGFR estimated glomerular filtration rate, Isa-Pd
isatuximab, pomalidomide, and dexamethasone, Pd pomalidomide and
dexamethasone.
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constipation, fatigue, back pain, and asthenia. Infections
were most frequently respiratory infections and less fre-
quently urinary tract infections. The incidence of upper
respiratory tract infections appeared similar in patients with
and without RI but were observed more frequently with Isa-
Pd than Pd, while lower respiratory infections were
observed more frequently in patient with RI in both treat-
ment arms. The types of infection experienced by patients in
the Isa-Pd and Pd arms stratified by renal function are
shown in Supplementary Table. Notably, there was a
similar exposure-adjusted rate of serious infections in the
overall population of the two study arms (0.72 per patient
year in the Isa-Pd arm and 0.67 per patient-year in the Pd
arm). Infusion-related reactions were observed in around
one-third of patients treated with Isa-Pd in both the RI and
non-RI groups.
In patients with RI at baseline, the incidence of grade ≥3
and serious TEAEs was higher with Isa-Pd (90.7% and
77.8%) than with Pd (78.7% and 59.6%; Table 2). When
adjusted for difference in exposure, the event rate of serious
TEAEs per patient-year was 1.90 with Isa-Pd and 1.94 with
Pd. In patients without RI at baseline, the incidence of grade
≥3 and serious TEAEs was 86.0% and 51.2% versus 67.0%
and 51.1% in the Isa-Pd and Pd groups, respectively. There
was no increased incidence of grade 5 TEAEs or of TEAEs
leading to treatment discontinuation with Isa-Pd versus Pd
in patients with RI (9.3% vs 12.8% and 11.1% vs 14.9%)
and in patients without RI (3.5% vs 6.4% and 5.8% vs
11.7%; Table 2).
PK analyses in patients with RI at baseline
Renal function was not identified as an influential covariate
on Isa PK. The model predicted a mean area under the curve
over the dosing interval of 2 weeks at steady state of 73,200
μg.h/mL (coefficient of variation [CV] 75.6%) in patients
with severe RI (N= 12; eGFR <30 mL/min/1.73 m²), of
74,600 μg.h/mL (CV 59.2%) in patients with moderate RI
(N= 163; eGFR ≥30 and <60 mL/min/1.73 m²), and of
77,700 μg.h/mL (CV 58.0%) in patients with mild RI (N=
192; eGFR ≥60 mL/min/1.73 m² and <90 mL/min/1.73 m²).
Taking account of interpatient variability, these values are
comparable to those of patients with normal renal function
(78,400 μg.h/mL; CV 53.6%).
Discussion
Renal impairment is an independent predictor of poor
prognosis in patients with RRMM, and there is a critical
need for anti-myeloma therapies that also improve renal
function. This prespecified subgroup analysis of ICARIA-
MM—the first randomized phase 3 study to demonstrate a
significant survival benefit of an anti-CD38 therapy (Isa)
Table 2 TEAEs by baseline
renal function and
treatment arm.
n (%) eGFR <60 mL/min/1.73 m² eGFR ≥60 mL/min/1.73 m²
Isa-Pd (n= 54) Pd (n= 47) Isa-Pd (n= 86) Pd (n= 94)
Median treatment duration, weeks
(range)
41.6 (4.0–74.1) 19.3 (1.0–65.0) 43.6 (3.1–76.7) 28.6 (1.7–73.7)
Any TEAE 54 (100.0) 47 (100.0) 85 (98.8) 91 (96.8)
Infectionsa 49 (90.7) 30 (63.8) 67 (77.9) 62 (66.0)
Cardiac disordersa 12 (22.2) 1 (2.1) 10 (11.6) 5 (5.3)
Gastrointestinal disordersa 30 (55.6) 28 (59.6) 46 (53.5) 44 (46.8)
General disorders and
administration site conditionsa
29 (53.7) 32 (68.1) 45 (52.3) 53 (56.4)
Grade ≥3 TEAE 49 (90.7) 37 (78.7) 74 (86.0) 63 (67.0)
Infectionsa 30 (55.6) 18 (38.3) 33 (38.4) 27 (28.7)
Pneumoniab 14 (25.9) 11 (23.4) 11 (12.8) 12 (12.8)
Musculoskeletal disordersa 9 (16.7) 3 (6.4) 3 (3.5) 3 (3.2)
Grade 5 TEAE 5 (9.3) 6 (12.8) 3 (3.5) 6 (6.4)
Serious TEAE 42 (77.8) 28 (59.6) 44 (51.2) 48 (51.1)
TEAE leading to definitive treatment
discontinuation
6 (11.1) 7 (14.9) 5 (5.8) 11 (11.7)
eGFR estimated glomerular filtration rate, Isa isatuximab, Pd pomalidomide and dexamethasone, RI renal
impairment, SOC system organ class, TEAE treatment-emergent adverse event.
aSOC with TEAEs with an incidence ≥10% greater in patients with versus without RI in the same arm.
bGrade ≥3 TEAE with an incidence ≥10% greater in patients with versus without RI in the same arm, among
SOCs defined ina.
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plus Pd versus Pd in heavily pretreated patients with
RRMM [22]—shows that Isa-Pd is also efficacious with a
manageable safety profile in patients with RI.
The addition of Isa to the Pd backbone in patients with RI
in ICARIA-MM resulted in a HR for PFS of 0.50 (95% CI,
0.30–0.85) in favor of patients receiving Isa-Pd versus Pd,
consistent with the observed PFS benefit of Isa-Pd in patients
without RI (HR 0.58; 95% CI, 0.38–0.88) and the overall
study population (HR 0.596; 95% CI, 0.44–0.81) [22]. PFS
observed among patients receiving Pd in ICARIA-MM
(3.7 months) was also consistent with previously recorded
results of the MM-003 study, where a similar median PFS of
4.0 months in patients with RI (eGFR <60mL/min/1.73m²)
was observed for patients treated with Pd [17].
The ORR was greater with Isa-Pd than Pd in patients
with RI (56.4% vs 24.5%) and without RI (67.8% vs
42.7%), again consistent with the overall study population
(Isa-Pd, 60.4%; Pd, 35.3%) [22]. Indeed, the ORR with Isa-
Pd was similar between patients with mild RI (eGFR ≥45–
<60 mL/min/1.73 m²; ORR 68.6%) and patients without RI.
Although OS data for ICARIA-MM are not fully mature,
a favorable HR of 0.53 can already be observed with the
upper limit of the 95% CI not crossing 1 (95% CI,
0.30–0.96).
Notably, compared with Pd, Isa-Pd increased the
proportion of RRMM patients with RI who achieved both
complete (71.9% with Isa-Pd, 38.1% with Pd) and sustained
(≥60 days; 31.3% vs 19.0%) renal responses, supporting
a role for Isa-Pd in achieving durable reversal of RI.
Correspondingly, fewer patients in the Isa-Pd group com-
pared with the Pd group experienced worsening of renal
function to severe RI or ESRD. In these renally impaired
patients, tumor response rates were higher in those with
renal response than those without renal response. The
higher rate of renal response experienced by patients in the
Isa-Pd arm contributes importantly to the higher tumor
response and hence benefit of this regimen over Pd.
The results of the ICARIA-MM subgroup analysis
provide the first evidence of improvement in renal function
with a CD38-targeted therapy in patients with RRMM. Data
Table 3 Most common
(occurring in ≥15% of patients)
TEAEs by baseline renal
function and treatment arm.
n (%) eGFR <60 mL/min/1.73 m2 eGFR ≥60 mL/min/1.73 m2
Isa-Pd (n= 54) Pd (n= 47) Isa-Pd (n= 86) Pd (n= 94)




16 (29.6) 6 (12.8) 27 (31.4) 19 (20.2)
Bronchitis 11 (20.4) 2 (4.3) 21 (24.4) 9 (9.6)
Pneumonia 16 (29.6) 12 (25.5) 15 (17.4) 14 (14.9)
Blood and lymphatic system disorders
Neutropenia 24 (44.4) 19 (40.4) 43 (50.0) 29 (30.9)
Thrombocytopenia 8 (14.8) 8 (17.0) 10 (11.6) 9 (9.6)
Febrile neutropenia 9 (16.7) 3 (6.4) 8 (9.3) 0
Respiratory, thoracic and mediastinal disorders
Dyspnea 5 (9.3) 5 (10.6) 16 (18.6) 9 (9.6)
Gastrointestinal disorders
Diarrhea 15 (27.8) 14 (29.8) 22 (25.6) 14 (14.9)
Constipation 7 (13.0) 8 (17.0) 16 (18.6) 17 (18.1)
Nausea 6 (11.1) 7 (14.9) 16 (18.6) 7 (7.4)
Musculoskeletal and connective tissue disorders
Back pain 14 (25.9) 7 (14.9) 11 (12.8) 15 (16.0)
General disorders and administration site conditions
Fatigue 10 (18.5) 13 (27.7) 16 (18.6) 18 (19.1)
Peripheral edema 5 (9.3) 6 (12.8) 15 (17.4) 10 (10.6)
Pyrexia 12 (22.2) 10 (21.3) 8 (9.3) 9 (9.6)
Asthenia 6 (11.1) 11 (23.4) 12 (14.0) 15 (16.0)
Procedural complications
Infusion-related reaction 18 (33.3) 1 (2.1) 34 (39.5) 1 (1.1)
eGFR estimated glomerular filtration rate, Isa isatuximab, Pd pomalidomide and dexamethasone, TEAE
treatment-emergent adverse event.
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on the anti-CD38 agent daratumumab in RRMM patients
with RI are currently limited to small uncontrolled studies or
case reports with single patients [23, 24]. Data on
elotuzumab, a humanized monoclonal antibody that binds
signaling lymphocyte activation molecule F7 (SLAMF7), are
also lacking in patients with RRMM and RI [5]. In a phase
1b study of elotuzumab in combination with lenalidomide
and dexamethasone, there were no complete renal responses
observed; two patients with severe RI showed minor renal
responses. ORRs observed among patients with severe RI
and ESRD were 67 and 56%, respectively, compared with an
ORR of 75% among patients with normal renal function
[25]. The phase 2 ELOQUENT-3 study of elotuzumab in
combination with Pd in patients with RRMM excluded
patients with creatinine clearance <45mL/min, hence there
are no data on efficacy or safety data for elotuzumab in an RI
population below this threshold [5].
In contrast with lenalidomide [6], pomalidomide can be
safely administered to patients with RI without dose
modification [26], and has previously been investigated in
subgroups of patients with RI. Similar renal responses to the
Pd arm of ICARIA-MM were observed in a subgroup
analysis of the phase 3 MM-003 trial comparing Pd versus
high-dose dexamethasone in RRMM [17]. The complete
renal response rate among patients with RI was 42% with
Pd in MM-003, consistent with 38.1% for patients receiving
Pd in ICARIA-MM. Pomalidomide in combination with
low-dose dexamethasone was also investigated in the phase
2 MM-013 trial. Among patients with moderate RI (eGFR
30 to <45 mL/min/1.73 m²), sustained renal responses were
observed in 18.2% of patients [18], mirroring the 19.0%
durable complete renal response rate in the Pd arm of
ICARIA-MM in patients with creatinine clearance <50 mL/
min/1.73 m2.
The addition of Isa to the Pd backbone had a manageable
safety profile in RRMM patients with and without RI. The
incidence of TEAEs of any grade or of grade ≥3 was
broadly similar between the renal subgroups. TEAEs
observed to occur at a more than 10% higher incidence in
the Isa-Pd arm in patients with versus without RI were
cardiac disorders (any grade), musculoskeletal disorders
(grade ≥3), and infections (any grade and grade ≥3), with
pneumonia identified as a driver behind the increased grade
≥3 infections. Grade ≥3 pneumonia was also observed to
have a more than 10% higher incidence in patients with RI
than those without RI in the Pd arm, suggesting that patients
with RI should be carefully monitored for lower respiratory
tract infections. Incidence of infusion-related reactions were
similar between the RI and non-RI groups. Among patients
with RI at baseline, the incidence of grade ≥3 and serious
TEAEs was greater in the Isa-Pd versus Pd arm, but this did
not translate to an increased incidence of grade 5 TEAEs or
TEAEs leading to treatment discontinuation. Notably,
patients in the Isa-Pd arm had increased treatment exposure
compared with patients in the Pd arm, which may have led
to a higher incidence of AEs in the Isa-Pd arm. When
adjusted for difference in exposure, the event rate of serious
TEAEs per patient year for patients with RI was similar in
the Isa-Pd and Pd arms, and the event rate of serious
infections per patient-year was similar in the two
study arms.
Rather than being renally excreted, protein therapeutics
are eliminated from the body nearly exclusively by
proteolysis, to which the kidneys may substantially con-
tribute as a major site for protein catabolism [27]. The PK of
Isa was not modified by altered renal function, which was as
expected since monoclonal antibodies are not renally
excreted. In addition, it has been shown that the PK of
pomalidomide is not modified in patients with RI [28].
Therefore, there is no PK-based need for dose adjustment in
RI patients.
The large study population, combined with the
multicenter, prospective design, support the study findings
as representative of Isa safety and efficacy in these patients.
Furthermore, fixed-volume infusion (250 mL) of Isa may
help with the management of fluid balance in patients with
RI [6, 29]. While the study used the validated IMWG cri-
teria to classify RI status, this was not a stratification factor
in the ICARIA-MM trial, which likely explains small
imbalances between the renal function subgroups. We also
acknowledge that few patients in this study had severe RI
and none were receiving hemodialysis; therefore, our ana-
lysis is most applicable to the moderate RI population.
In summary, the addition of Isa to Pd improved PFS and
ORR in patients with RI, consistent with the benefit
observed in patients without RI and the overall RRMM
study population. Isa-Pd also increased the number of
patients with reversal of RI and sustained renal responses
compared with Pd. Based on these findings, and the absence
of any need for dose adjustments based on renal function,
Isa-Pd represents a valuable treatment option for patients
with RRMM presenting with renal dysfunction.
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